| Rebinyn |
125611 |
003 |
351(a) |
Coagulation Factor IX (Recombinant), GlycoPEGylated |
For Injection |
Intravenous |
1000IU |
Single-Dose Vial |
2017/05/31
|
Novo Nordisk Inc. |
Rx |
Licensed |
|
N/A |
| Zinbryta |
761029 |
002 |
351(a) |
daclizumab |
Injection |
Subcutaneous |
150MG/ML |
Autoinjector |
2017/05/26
|
Biogen Inc. |
Disc |
Voluntarily Revoked |
N/A |
N/A |
| Kevzara |
761037 |
001 |
351(a) |
sarilumab |
Injection |
Subcutaneous |
150MG/1.14ML |
Pre-Filled Syringe |
2017/05/22
|
Sanofi-Aventis U.S. LLC |
Rx |
Licensed |
N/A |
N/A |
| Kevzara |
761037 |
002 |
351(a) |
sarilumab |
Injection |
Subcutaneous |
200MG/1.14ML |
Pre-Filled Syringe |
2017/05/22
|
Sanofi-Aventis U.S. LLC |
Rx |
Licensed |
N/A |
N/A |
| Imfinzi |
761069 |
001 |
351(a) |
durvalumab |
Injection |
Intravenous |
500MG/10ML (50MG/ML) |
Single-Dose Vial |
2017/05/01
|
AstraZeneca UK Ltd |
Rx |
Licensed |
N/A |
N/A |
| Imfinzi |
761069 |
002 |
351(a) |
durvalumab |
Injection |
Intravenous |
120MG/2.4ML (50MG/ML) |
Single-Dose Vial |
2017/05/01
|
AstraZeneca UK Ltd |
Rx |
Licensed |
N/A |
N/A |
| Humira |
125057 |
010 |
351(a) |
adalimumab |
Injection |
Subcutaneous |
20MG/0.2ML |
Pre-Filled Syringe |
2017/04/28
|
AbbVie Inc. |
Rx |
Licensed |
N/A |
N/A |
| Humira |
125057 |
011 |
351(a) |
adalimumab |
Injection |
Subcutaneous |
10MG/0.1ML |
Pre-Filled Syringe |
2017/04/28
|
AbbVie Inc. |
Rx |
Licensed |
N/A |
N/A |
| Brineura |
761052 |
001 |
351(a) |
cerliponase alfa |
Injection |
Intraventricular |
150MG/5ML (30MG/ML) |
Single-Dose Vial |
2017/04/27
|
BioMarin Pharmaceutical Inc. |
Rx |
Licensed |
N/A |
N/A |
| Humira |
125057 |
009 |
351(a) |
adalimumab |
Injection |
Subcutaneous |
80MG/0.8ML |
Autoinjector |
2017/04/21
|
AbbVie Inc. |
Rx |
Licensed |
N/A |
N/A |
| Renflexis |
761054 |
001 |
351(k) Biosimilar |
infliximab-abda |
For Injection |
Intravenous |
100MG |
Single-Dose Vial |
2017/04/21
|
Samsung Bioepis Co., Ltd. |
Rx |
Licensed |
infliximab |
Remicade |
| Afstyla |
125591 |
006 |
351(a) |
Antihemophilic Factor (Recombinant), Single Chain |
For Injection |
Intravenous |
2500IU |
Single-Dose Vial |
2017/03/31
|
CSL Behring Lengnau AG |
Rx |
Licensed |
|
N/A |
| Afstyla |
125591 |
007 |
351(a) |
Antihemophilic Factor (Recombinant), Single Chain |
For Injection |
Intravenous |
1500IU |
Single-Dose Vial |
2017/03/31
|
CSL Behring Lengnau AG |
Rx |
Licensed |
|
N/A |
| Orencia |
125118 |
004 |
351(a) |
abatacept |
Injection |
Subcutaneous |
50MG/0.4ML |
Pre-Filled Syringe |
2017/03/30
|
Bristol-Myers Squibb Company |
Rx |
Licensed |
N/A |
N/A |
| Orencia |
125118 |
005 |
351(a) |
abatacept |
Injection |
Subcutaneous |
87.5MG/0.7ML |
Pre-Filled Syringe |
2017/03/30
|
Bristol-Myers Squibb Company |
Rx |
Licensed |
N/A |
N/A |
| Ocrevus |
761053 |
001 |
351(a) |
ocrelizumab |
Injection |
Intravenous |
300MG/10ML (30MG/ML) |
Single-Dose Vial |
2017/03/28
|
Genentech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Dupixent |
761055 |
001 |
351(a) |
dupilumab |
Injection |
Subcutaneous |
300MG/2ML |
Pre-Filled Syringe |
2017/03/28
|
Regeneron Pharmaceuticals, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Dupixent |
761055 |
002 |
351(a) |
dupilumab |
Injection |
Subcutaneous |
300MG/2ML |
Pre-Filled Syringe |
2017/03/28
|
Regeneron Pharmaceuticals, Inc. |
Disc |
Licensed |
N/A |
N/A |
| Bavencio |
761049 |
001 |
351(a) |
avelumab |
Injection |
Intravenous |
200MG/10ML (20MG/ML) |
Single-Dose Vial |
2017/03/23
|
EMD Serono, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Adynovate |
125566 |
007 |
351(a) |
Antihemophilic Factor (Recombinant), PEGylated |
For Injection |
Intravenous |
3000IU |
Single-Dose Vial |
2017/03/13
|
Takeda Pharmaceuticals U.S.A., Inc. |
Rx |
Licensed |
|
N/A |